Navigation Links
Neurofocus Appoints Stephen Kosslyn to Its Advisory Board
Date:9/17/2008

Professor And Former Chair Of Psychology Department At Harvard University Joins Panel Of Leaders In Business, Academia And Science At World's Leading

Neurological Testing Company

BERKELEY, Calif., Sept. 17 /PRNewswire/ -- NeuroFocus, Inc., the world's leading company in the field of neurological testing for marketing research, announced that professor Stephen Kosslyn, Ph.D. has joined the firm's Advisory Board.

He is the John Lindsley Professor of Psychology and former Chair of the Department of Psychology at Harvard University. He has published over 300 scientific papers, and is one of the founding fathers of the field of cognitive neuroscience.

"We are privileged to have someone of Dr. Kosslyn's stature lending his presence to our Advisory Board," said Dr. A. K. Pradeep, Chief Executive Officer of NeuroFocus. "It underscores our foundation as the most strongly science-based company in the neurological testing category, which in turn is the foundation for our clear leadership in that category."

Dr. Kosslyn's academic accomplishments have been recognized through awards bestowed by organizations including the American Psychological Association and the National Academy of Sciences, among many others. He was also granted a Guggenheim Fellowship and the Catell Award.

His achievements in research have focused primarily on the nature of visual perception, visual mental imagery, and visual communication. He has had several books published on these subjects, including "Image and Mind"; "Image and Brain"; "The Case for Mental Imagery"; "Graph Design for the Eye and Mind"; and "Clear and to the Point".

Dr. Kosslyn received his B.A. in psychology from UCLA, and his Ph.D. from Stanford University, also in psychology.

About NeuroFocus

NeuroFocus Inc. is the market leader in bringing neuroscience knowledge and expertise to the world of advertising, marketing, product development and packaging, a
'/>"/>

SOURCE NeuroFocus, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. NeuroFocus Chief Science Advisor Wins Humboldt Prize
2. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
3. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
4. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
5. China Yingxia International, Inc. Appoints New Vice President of Finance
6. SoluBest Appoints Michael Sheckler, MBA, as CEO
7. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
8. Affitech Appoints Dr. Keith McCullagh as Chairman
9. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
10. Algenol Biofuels Appoints Chief Science Officer
11. Axial Biotech appoints new Vice President of Strategic Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Synthetic protein mimics structure, function of metalloprotein in nature 2First phase of pan-tropical forest mapping debuting at COP15 2First phase of pan-tropical forest mapping debuting at COP15 3Potential new heart attack biomarker uncovered 2Anglo Americans Coal Division in South Africa Wins Global Business Coalition Award for top International Workplace HIV and AIDS Programme 49753 1Anglo Americans Coal Division in South Africa Wins Global Business Coalition Award for top International Workplace HIV and AIDS Programme 49753 2Anglo Americans Coal Division in South Africa Wins Global Business Coalition Award for top International Workplace HIV and AIDS Programme 49753 3Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 1Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 2Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 3Derma Sciences Announces First Commercial Sales of BIOGUARD 28TM 29 Barrier Dressings 49751 4Biovista Inc Announces Positive Efficacy Results in a Pre Clinical Trial of its BVA 601 Repositioned Drug for Epilepsy 12744 1Biovista Inc Announces Positive Efficacy Results in a Pre Clinical Trial of its BVA 601 Repositioned Drug for Epilepsy 12744 2